ライフサイエンスコーパス: arachidonate

1 h COX-1 and COX-2 enzyme isoforms with bound arachidonate.

2 compounds, analogous to those generated from arachidonate.

3 ed from in vitro autoxidation of cholesteryl arachidonate.

4 capillaries with respectively, TNF-alpha and arachidonate.

5 regioisomeric hydroperoxides of cholesteryl arachidonate.

6 ethyl linoleate < methyl linolenate < methyl arachidonate.

7 itation of the extracellular release of (3)H-arachidonate.

8 nd hydrolyzes only those that do not contain arachidonate.

9 oxygenase activity to produce 15R-HETE from arachidonate.

10 ics were observed for oleate, palmitate, and arachidonate.

11 tate, cholesteryl linoleate, and cholesteryl arachidonate.

12 E(2) synthesis in addition to its release of arachidonate.

13 e 2.47-A resolution crystal structure of the arachidonate 11R-LOX from Gersemia fruticosa, which shed

14 ALOX12 is a gene encoding arachidonate 12-lipoxygenase (12-LOX), a member of a non

15 d lower DNA methylation at a CpG site in the arachidonate 12-lipoxygenase (ALOX12) gene in children h

16 tegrative 'omics' analysis, we identified an arachidonate 12-lipoxygenase (ALOX12)-12-hydroxyeicosate

17 Furthermore, cGMP signalling activated by an arachidonate 12-lipoxygenase metabolite suppresses LCC a

18 te transporter beta), and 12-HETE synthesis (arachidonate 12-lipoxygenase) were significantly up-regu

19 etion of the genes encoding 12-lipoxygenase (arachidonate 12-lipoxygenase, 12S type [Alox12]) or 12/1

20 cycle, p53 status, or its purported target, arachidonate 12-lipoxygenase, but does require caspase a

21 0.01] and increased lipoxygenase expression (arachidonate 12-lipoxygenaseP< 0.05; arachidonate 15-lip

22 damage and tested the potential of targeting arachidonate 15-lipoxygenase (ALOX15) in treating alcoho

23 is correlated with the expression levels of arachidonate 15-lipoxygenase (ALOX15), and SAT1-induced

24 h2 cytokine IL-4 with elevated expression of arachidonate 15-lipoxygenase (ALOX15).

25 Here, we determined that the gene encoding arachidonate 15-lipoxygenase (Alox15/15-LO) is essential

26 T cells and IgG4 plasma cells; and abundant arachidonate 15-lipoxygenase and 25-hydroxyvitamin D-1 a

27 -related increases (>1.5-fold expression) in arachidonate 15-lipoxygenase and gamma-glutamyltransfera

28 alpain small subunit 1) and ALOX15 (encoding arachidonate 15-lipoxygenase), show significant associat

29 ism of activation of alveolar macrophages by arachidonate 15-lipoxygenase-derived eicosanoids to expr

30 ession (arachidonate 12-lipoxygenaseP< 0.05; arachidonate 15-lipoxygenaseP< 0.05) in the ovary.

31 Products of arachidonate 15-lipoxygenases (LO) types I and II displa

32 ic protein, the ribonucleases) together with arachidonate-15-lipoxygenase and protease inhibitor plas

33 Dramatic differences in arachidonate (20:4 fatty acid)-containing lipids were ob

34 e autoxidation propagation rate constants of arachidonate (20:4), eicosapentaenoate (20:5), docosahex

35 parts, with pronounced discrimination toward arachidonate (20:4n-6) and against eicosapentaenoate (20

36 th production of PA and metabolism of [(3)H]-arachidonate ([(3)H]AA)-labeled phospholipids by PLA(2)

37 Here we identify the arachidonate 5-lipoxygenase (5-LO) gene (Alox5) as a cri

38 We reported earlier that arachidonate 5-lipoxygenase (5-Lox) plays an important r

39 57BL/6J x CAST/Ei) F(2) cross and identified arachidonate 5-lipoxygenase (5LO) as a candidate gene in

40 ibition of the leukotriene-generating enzyme arachidonate 5-lipoxygenase (Alox5) abrogates neutrophil

41 ators derive from the same pathway, in which arachidonate 5-lipoxygenase (ALOX5) and its partner, ara

42 ell as infectious HIV-X4 remarkably increase arachidonate 5-lipoxygenase (ALOX5) expression.

43 copy numbers of the Sp1-binding motif in the arachidonate 5-lipoxygenase (ALOX5) gene promoter (eithe

44 Genotype at rs1864414 in the arachidonate 5-lipoxygenase ALOX5 was also associated wi

45 nate 5-lipoxygenase (ALOX5) and its partner, arachidonate 5-lipoxygenase-activating protein (ALOX5AP)

46 Arachidonate 5-lipoxygenase-activating protein (ALOX5AP)

47 Arachidonate-5-lipoxygenase (5-LO) activity and increase

48 ults were comparable with those generated by arachidonate, a known stimulator for this system.

49 psigargin and A23187 stimulated robust [(3)H]arachidonate (AA) release from wild-type aortic SMCs tha

50 -Lipoxygenase 2 (15-LOX2), the most abundant arachidonate (AA)-metabolizing enzyme expressed in adult

51 These data demonstrate that the arachidonate-activated entry of Ca(2+) occurs via an ent

52 forms of Ca(2+) entry, such as ionophore- or arachidonate-activated entry through the plasma membrane

53 tumor painting technique, we show that DDAO arachidonate activates to a high degree in basal-like ve

54 arying breast cancer sub-types, we show DDAO arachidonate activates with a high correlation to cPLA2a

55 mutant proteins of CYP4A7 found laurate and arachidonate activity markedly diminished in the R90W mu

56 Arachidonate also blocked the activation of a synthetic

57 14-eicosatetraynoic acid, a nonmetabolizable arachidonate analogue, also inhibited cell growth, sugge

58 inhibited by 10 microm quinidine, 20 microm arachidonate and acid (pH 6.3) at 49, 43, and 23%, respe

59 hanges in vitreous lipid autacoids including arachidonate and docosahexanoate-derived metabolites ind

60 Thus, in the presence of arachidonate and in the absence of lipid-soluble antioxi

61 f peripheral blood monocytes, and release of arachidonate and leukotriene from several cell types in

62 f peripheral blood monocytes, and release of arachidonate and leukotriene from several cell types.

63 hat are generated upon oxidative cleavage of arachidonate and linoleate esters of 2-lysophosphatidylc

64 lly directing oxygen to different carbons of arachidonate and other polyunsaturated acyl chains, but

65 In vitro, arachidonate and other unsaturated fatty acids competiti

66 leukin-1beta leads to synergistic release of arachidonate and production of prostaglandin E(2).

67 lternate binding site for the carboxylate of arachidonate and that it is not the only specificity det

68 an ionic bond with the carboxylate group of arachidonate and that this interaction is an important c

69 ther insights into the oxidation products of arachidonate and the opportunity to study their potentia

70 M, and N-(2-formyl)-pyrrolo-PM (derived from arachidonate), and N-formyl-PM and N-hexanoyl-PM (derive

71 ze phospholipids to a free fatty acid, e.g., arachidonate, and a 2-lysophospholipid.

72 te, myristate, palmitate, oleate, linoleate, arachidonate, and docosahexanoate), or fatty alcohols (p

73 The PGHS substrate, arachidonate, and various cyclooxygenase inhibitors do n

74 ollowing wounding and (ii) indicate that the arachidonate- and jasmonate-response pathways are distin

75 NMDA application in WT and arachidonate applied to cPLA(2)alpha null cells occluded

76 Short-term depression and the release of arachidonate are blocked by the specific p38 kinase inhi

77 We concluded that higher amounts of free arachidonate are made available for the generation of ac

78 osphatidic acid and free fatty acids such as arachidonate are potent activators of PLCepsilon, increa

79 The Km values of PGHS-1 and -2 for arachidonate are the same, and all but one of the core r

80 achidonate consumed) for mixtures containing arachidonate as the only oxidizable PUFA, but yields of

81 g in exposing the cells to deuterium-labeled arachidonate at the time they are exposed to stimuli, we

82 silver cation to bind to the polyunsaturated arachidonate backbone of both molecules to form the char

83 dicted to be significantly more complex than arachidonate because of the fact that EPA contains an ad

84 48); (c) residues critical for high affinity arachidonate binding (Arg-120); (d) residues critical fo

85 and 4 other closely neighboring residues in arachidonate binding and oxygenation.

86 These combined effects of arachidonate binding by ferritin are expected to lower b

87 Arachidonate binding by ferritin enhanced iron mineraliz

88 ic potentials were determined for oleate and arachidonate binding to a subset of the FABP and retinoi

89 rtant contributor to the overall strength of arachidonate binding to PGHS-1.

90 this interaction is much less important for arachidonate binding to PGHS-2 than to PGHS-1.

91 ity, that has proved to be inappropriate for arachidonate-binding to mammalian 5-, 12- and 15-lipoxyg

92 After incubation in medium supplemented with arachidonate but deprived of lipid-soluble antioxidants,

93 ADRP also stimulated uptake of palmitate and arachidonate but had no effect on uptake of medium chain

94 es in kinetic values for CoA, palmitate, and arachidonate, but their apparent Km values for oleate we

95 e site, we analyzed the products formed from arachidonate by (a) solubilized, partially purified ovin

96 regioisomers and enantiomers are formed from arachidonate by inducible cytochrome P450 epoxygenase is

97 etected from the autoxidation of cholesteryl arachidonate by LC-MS and GC-MS techniques.

98 Oxidative cleavage of arachidonate (C(20)) and linoleate (C(18)) phospholipids

99 The finding that arachidonate can also induce a conformational change in

100 These results establish that arachidonate can assume at least three catalytically pro

101 s (those leading to 12-HPETE and 8-HPETE) of arachidonate can form these new peroxides.

102 n, the phospholipase A(2) (PLA(2))-activated arachidonate cascade, and activator protein (AP)-1-assoc

103 us, three lipid mixtures containing the same arachidonate concentration but different amounts of othe

104 enase activity has a cooperative response to arachidonate concentration, whereas the second isoform,

105 med after 1 h of oxidation was 18% (based on arachidonate consumed) for mixtures containing arachidon

106 ntiated cells contain a higher proportion of arachidonate-containing GPC species than control cells.

107 hydes generated by free radical oxidation of arachidonate-containing lipids through the isoprostane p

108 tric analyses indicate that the abundance of arachidonate-containing PC species of islets, brain, and

109 at, contrary to cPLA2alpha, iPLA2beta spares arachidonate-containing phospholipids and hydrolyzes onl

110 yed an increase in phosphatidylinositols and arachidonate-containing phospholipids that can serve as

111 based lipid profiling to study the levels of arachidonate-containing phospholipids under inflammatory

112 esponse results in the intense remodeling of arachidonate-containing phospholipids, leading to the mo

113 Arachidonate-containing plasmenylethanolamine phospholip

114 (hDGK epsilon) displays high selectivity for arachidonate-containing substrates and may be essential

115 The differences in arachidonate content between the two cell lines were gre

116 concomitant with a 40.7 +/- 8.1% decrease in arachidonate content in phosphatidylethanolamine (PE), s

117 ing the levels of unesterified EETs and that arachidonate controls the expression of its activator Ac

118 or production by LTA4 hydrolase and to block arachidonate conversion by human 12-LOX rather than mere

119 +/- 8 for the portal mutant, while that for arachidonate decreased from the wild type of 186 +/- 11

120 The neutral arachidonate derivative, 2-arachidonylglycerol (2-AG), i

121 xide (NO) modulates the biological levels of arachidonate-derived cell signaling molecules by either

122 ediators, among which only omega-6 (omega-6) arachidonate-derived eicosanoids have been well characte

123 markedly reduced levels of pro-inflammatory arachidonate-derived F2-IsoPs by up to 64% (p < 0.05).

124 lipids are homologues of biologically active arachidonate-derived phospholipids.

125 Lipoxins (LX) are arachidonate-derived pro-resolving mediators that are de

126 ir obvious potential as markers for specific arachidonate-derived protein modifications that may be o

127 anogram amounts by platelets from endogenous arachidonate during physiological activation, with inhib

128 s were localized at branch points, while the arachidonate effects were nonlocalized and extensive.

129 polyunsaturated fatty acids (PUFAs) such as arachidonate, eicosapentaenate, and docosahexaenate (DHA

130 nctionally linked to PLC and cytochrome P450 arachidonate epoxygenase activity.

131 (a) a self-sufficient, catalytically active arachidonate epoxygenase can be constructed by fusing P4

132 This study demonstrates that a P450 arachidonate epoxygenase metabolite can activate cleavag

133 trienoic acids, products of the kidney P-450 arachidonate epoxygenase, inhibit distal nephron Na(+) r

134 of phospholipase C (PLC) or cytochrome P450 arachidonate epoxygenase.

135 Pharmacological inhibition of brain P450 arachidonate epoxygenases also blocked morphine antinoci

136 n the ability to release a large fraction of arachidonate esterified in phospholipids when stimulated

137 ing Jak2-compromised cultures with exogenous arachidonate failed to increase PGE(2) production in res

138 s occurs via the sequential incorporation of arachidonate, first into the sn-2 position of a preforme

139 ) residues essential for positioning C-13 of arachidonate for hydrogen abstraction (Gly-533 and Tyr-3

140 A(2) acts on the nuclear envelope to provide arachidonate for other enzymes involved in the eicosanoi

141 enotype, Cyp 4a12 expression, and 20-hydroxy-arachidonate formation.

142 ply rationalized by a kinetic model in which arachidonate forms various catalytically competent arran

143 roup IIa secretory PLA2 (sPLA2) can generate arachidonate from cellular phospholipids.

144 ene (B(a)P) caused significant release of 3H-arachidonate from endothelial cells.

145 disproportionately more linoleate, and less arachidonate from lipoproteins.

146 diminished capacity of mast cells to remodel arachidonate from PC to PE pools.

147 tribution and reduces the rate of release of arachidonate from phospholipids.

148 hospholipases A(2) work together to liberate arachidonate from RGM1 cell phospholipids in response to

149 e to a bromoenol lactone inhibitor catalyzes arachidonate hydrolysis from phospholipids in some cells

150 -120); (d) residues critical for positioning arachidonate in a conformation so that when hydrogen abs

151 The availability of free arachidonate in cells for subsequent eicosanoid biosynth

152 reveal different conformational behavior for arachidonate in each subunit over the course of extended

153 gue for the existence of segregated pools of arachidonate in human neutrophils.

154 However, there was an increase in arachidonate in phosphatidylcholine (PC) and neutral lip

155 were compared with reference simulations of arachidonate in solution to explore the effect of enzyme

156 rolonged incubation of Huh7-K2040 cells with arachidonate in the absence of lipid-soluble antioxidant

157 ies designed to determine the orientation of arachidonate in the cyclooxygenase site, we analyzed the

158 position and 36 and 40%, respectively, more arachidonate in the sn-2 position.

159 rmed in incubations of PM with linoleate and arachidonate in vitro, are also excreted in the urine of

160 ific fatty acids, particularly palmitate and arachidonate, in phospholipids.

161 inhibition reduces LPC levels and suppresses arachidonate incorporation and phospholipid remodeling i

162 phospholipids in some cells and facilitates arachidonate incorporation into glycerophosphocholine (G

163 he PAPH inhibitor propranolol did not affect arachidonate incorporation into islet or INS-1 cell phos

164 Arachidonate incorporation into islet phospholipids invo

165 but iPLA(2) inhibition impairs neither [(3)H]arachidonate incorporation into nor release from U937 ce

166 ls are nearly identical, as are the rates of arachidonate incorporation into PC and the composition a

167 l 2-lysophosphatidylcholine (LPC) levels and arachidonate incorporation into phosphatidylcholine (PC)

168 sophosphatidylcholine (LPC) levels, rates of arachidonate incorporation into phospholipids, and degra

169 did not suppress and generally enhanced [3H]arachidonate incorporation into these cells in the prese

170 on of iPLA(2)beta does not impair macrophage arachidonate incorporation or phospholipid composition.

171 INS-1 cells, iPLA2 is thus not required for arachidonate incorporation or phospholipid remodeling an

172 m the free radical-initiated peroxidation of arachidonate independent of COX and is composed of PGF(2

173 m the free radical-catalyzed peroxidation of arachidonate independent of COX.

174 lockers inhibited the TNF-alpha- but not the arachidonate-induced responses.

175 t R120L hPGHS-2 catalyzes the oxygenation of arachidonate inefficiently.

176 hose reported after [1-(14)C]AA (the natural arachidonate) infusion in mice.

177 amide moiety of AEA, like the carboxylate of arachidonate, interacts with Arg-120 at the bottom of th

178 associated with increased incorporations of arachidonate into liver phosphatidylcholine and phosphat

179 que ability to catalyze the incorporation of arachidonate into membranes.

180 onverts polyunsaturated fatty acids, such as arachidonate, into reactive carbonyls that inactivate pr

181 itro showed that the formation of IsoPs from arachidonate is dramatically influenced by the presence

182 The released arachidonate is metabolized by 12-lipoxygenase to active

183 The essential fatty acid arachidonate is oxidized by cytochrome P-450 epoxygenase

184 t the interleukin-1beta-dependent release of arachidonate is promoted by secreted phospholipase A(2)

185 ained analogs did not partition into the [3H]arachidonate-labeled U937 membranes as effectively as co

186 As a consequence of this process, the arachidonate levels in membrane phospholipids markedly d

187 s to determine FFAu profiles for mixtures of arachidonate, linoleate, oleate, palmitate, and stearate

188 esolving mediator (SPM) biosynthetic enzymes arachidonate lipoxygenase (ALOX) 12 and ALOX15 and up-re

189 The increase in arachidonate may be functionally significant in terms of

190 2alpha activatable fluorophores such as DDAO arachidonate may serve as a useful contrast agent for th

191 xhibited remarkable increases in laurate and arachidonate metabolism (3-fold) above wild-type substra

192 we examined the expression of key enzymes of arachidonate metabolism and inflammatory genes in untrea

193 The 12/15-lipoxygenase pathway of arachidonate metabolism and its lipid products have also

194 12-Lipoxygenase (12-LO) products of arachidonate metabolism have growth and chemotactic effe

195 We concluded that stimulation of arachidonate metabolism in S49 murine lymphoma cells by

196 mbinant P-450s 2C11, 2C23, and 2C24 catalyze arachidonate metabolism to mixtures of epoxy- and monohy

197 attractant protein-1, and 2 major enzymes of arachidonate metabolism, namely, 12/15-lipoxygenase and

198 pression of 12-lipoxygenase (12-LOX) and its arachidonate metabolite 12-hydroxy-5Z,8Z,10E,14Z-eicosat

199 logical feedback mechanism between these two arachidonate metabolite classes.

200 However, the endogenous arachidonate metabolite N-arachidonyldopamine (NADA) pro

201 rienoyl)glycerol (2-14,15-EG), a novel cP450 arachidonate metabolite produced in the kidney, is a pot

202 rain concentration of prostaglandin E(2), an arachidonate metabolite produced via cyclooxygenase 2.

203 irst evidence of a cytochrome P450-dependent arachidonate metabolite that can activate G-protein-coup

204 nd is converted efficiently into more stable arachidonate metabolites (PGD(2), PGE(2), and PGF(2)) by

205 nd is efficiently converted into more stable arachidonate metabolites (PGD(2), PGE(2), and PGF(2)) by

206 as arachidonic acid, from phospholipids, and arachidonate metabolites are recognized mediators of bon

207 nd is efficiently converted into more stable arachidonate metabolites by the action of enzymes.

208 ation on the functional role of P450-derived arachidonate metabolites in mammals, we postulate that C

209 min produced significantly higher amounts of arachidonate metabolites than did platelets incubated wi

210 al blood gases, and plasma concentrations of arachidonate metabolites were measured hourly over a 4-h

211 sv-b, a splice variant that does not possess arachidonate-metabolizing activity, show a passage-relat

212 -lipoxygenase 2 (15-LOX2), the most abundant arachidonate-metabolizing LOX in adult human prostate an

213 oup V sPLA(2) was able to induce significant arachidonate mobilization on its own and to induce expre

214 Cholesteryl arachidonate modified with 12/15LO also activated macrop

215 llowed by the rapid introduction of a second arachidonate moiety into the sn-1 position.

216 s (a) establish a physiological role for the arachidonate monooxygenases in renal sodium reabsorption

217 ave suggested a role for the cytochrome P450 arachidonate monooxygenases in the pathophysiology of hy

218 t the androgen-mediated regulation of Cyp 4a arachidonate monooxygenases is an important component of

219 ) mice and minimizes Cyp 4a12 expression and arachidonate omega-hydroxylation.

220 ear stress; 2) aggregation induced by sodium arachidonate or ADP; 3) agonist-induced thromboxane prod

221 and retained in the cell or secreted as free arachidonate or leukotrienes.

222 Exposing INS 832/13 cells to arachidonate or linoleate reduced Acsl4 mRNA and protein

223 BARS active compounds present in cholesteryl arachidonate oxidation mixtures.

224 cation of this protein with isolevuglandins, arachidonate oxidation products.

225 idonic acid and has been reported to inhibit arachidonate oxygenation by prostaglandin endoperoxide s

226 eatment had no effect on the maximal rate of arachidonate oxygenation.

227 e initially generated in situ, i.e. when the arachidonate precursor is esterified in phospholipids, a

228 d 2-arachidonoylglycerol to generate a major arachidonate precursor pool for neuroinflammatory prosta

229 parin, it is shown that hGIIA liberates free arachidonate prior to secretion from the cell.

230 F(2)-isoprostanes (F(2)-IsoPs) are arachidonate products formed on membrane phospholipids b

231 rosal suggests a critical regulatory role of arachidonate reacylation that limits leukotriene biosynt

232 ults strongly implicate MBOAT5 and MBOAT7 in arachidonate recycling, thus regulating free arachidonic

233 to a change in K(m) for substrate; 50 microM arachidonate reduced the K(m) for the soluble PLC substr

234 2+) (CRAC) channels, the recently identified arachidonate-regulated Ca(2+) (ARC) channels display a l

235 o increased in a store-independent manner by arachidonate-regulated Ca(2+) (ARC) channels.

236 -operated channels and the store-independent arachidonate-regulated Ca(2+)(ARC) channels are regulate

237 Recently, we have described a novel arachidonate-regulated Ca(2+)-selective (ARC) conductanc

238 ARC channels (arachidonate-regulated Ca(2+)-selective channels) are a

239 Ca2+-selective channels: the noncapacitative arachidonate-regulated Ca2+ channels (ARC channels) and

240 We have named this novel current I(ARC) (for arachidonate-regulated calcium current).

241 The arachidonate-regulated, Ca(2+)-selective ARC channels re

242 oduces both a reduction in the larger second arachidonate release and a blockade of induced cyclooxyg

243 idic calcium-independent PLA2, attenuated 3H-arachidonate release and apoptosis by PA, but not 1-MA o

244 bitor of Group VI enzymes, inhibited both 3H-arachidonate release and apoptosis induced by 1-MA and P

245 3H-arachidonate release and apoptosis induced by 1-MA, B(a)

246 ed from the rapid loss of IL-1beta-dependent arachidonate release and by attenuation of group IIA sec

247 DAG promotes arachidonate release by a mechanism that does not requir

248 ivation of p44/p42 MAP kinase and subsequent arachidonate release by cytoplasmic phospholipase A2 are

249 ant CHO-K1 cell lines, it is shown that this arachidonate release does not require heparan sulfate pr

250 IA secreted phospholipase A(2) contribute to arachidonate release from cytokine-stimulated RGM1 cells

251 t ionophore A23187 induces substantial [(3)H]arachidonate release from differentiated but not control

252 d after enzyme secretion, whereas all of the arachidonate release from HEK293 cells occurs prior to e

253 ne and the CaMKIIbeta inhibitor KN93 reduced arachidonate release from INS-1 insulinoma cells, and bo

254 internal cellular membranes as a prelude for arachidonate release from membrane phospholipids.

255 This novel signaling pathway for arachidonate release is shown to be cPLA(2)-dependent by

256 With hGX-transfected CHO-K1 cells, arachidonate release occurs before and after enzyme secr

257 A later sustained arachidonate release occurs during and after spreading,

258 An initial transient arachidonate release occurs during cell attachment to fi

259 h [3H]arachidonic acid display increased [3H]arachidonate release on exposure to AGE-albumin over exp

260 Similarly, LPS-induced arachidonate release was inhibited in cells transfected

261 investigate whether SCF-mediated priming of arachidonate release was mediated by this kinase.

262 i and cPLA(2) isoforms, completely inhibited arachidonate release without affecting ERK2 activation,

263 The second arachidonate release, and cyclooxygenase-2 expression an

264 Both the second sustained arachidonate release, and cyclooxygenase-2 protein induc

265 lipase A(2) (cPLA(2)), an enzyme involved in arachidonate release, are involved in many physiological

266 In the late phase of arachidonate release, group IIA secreted phospholipase A

267 , both dexamethasone and RU486 repressed [3H]arachidonate release, which is consistent with an effect

268 lated by cytokines nor does it contribute to arachidonate release.

269 ads to serum- and interleukin-1beta-promoted arachidonate release.

270 to significant inhibition of cPLA2-mediated arachidonate release.

271 The [(14)C]arachidonate released from mCD14-acquired [(14)C]arachid

272 TNF-alpha, but not arachidonate, released Ca(2+) from endoplasmic stores an

273 abrogated TNF-alpha responses partially, but arachidonate responses completely.

274 of NADPH oxidase activity is to control the arachidonate-sensitive assembly of the complete oxidase

275 y-state turnover rates with both laurate and arachidonate showed the trend WT > F393Y >> F393H > F393

276 its double bonds from solvent but allows the arachidonate tail to project well into the ferrihydrite

277 s did not appreciably alter the Km value for arachidonate, the cyclooxygenase product profile, or the

278 of cytosolic phospholipase A2 and release of arachidonate, the precursor of prostaglandin D2 and the

279 lower both intracellular free iron and free arachidonate, thereby providing a previously unrecognize

280 middle dot)NO consumption also occurs during arachidonate, thrombin, or activation of platelets (1-2

281 o group of Arg-120 of hPGHS-2 interacts with arachidonate through a hydrogen bond rather than an ioni

282 he cytochrome P450 enzyme system metabolizes arachidonate to 14,15-epoxyeicosatrienoic acid (14,15-EE

283 xidation on HCV replication, we administered arachidonate to Huh7 cells that harbor an HCV replicon (

284 mes catalyze a key step in the conversion of arachidonate to PGH2, the immediate substrate for a seri

285 of PGH(2) involves an initial oxygenation of arachidonate to yield PGG(2) catalyzed by the cyclooxyge

286 ins included MRP-14, potentially involved in arachidonate transport, and ribosomal subunit proteins a

287 In contrast, arachidonate treatment strongly suppressed hmg1 and stro

288 Lithium's reduction of arachidonate turnover corresponded to its down-regulatin

289 Arachidonate turnover in rat brain also was reduced by l

290 nvolved in hydrogen abstraction from C-13 of arachidonate (Tyr-385); (b) residues essential for posit

291 ospholipid head-group classes into which [3H]arachidonate was initially incorporated or its subsequen

292 g a cPLA2alpha activatable fluorophore, DDAO arachidonate, we explore its ability to function as a co

293 ons of cholesteryl linoleate and cholesteryl arachidonate were active against P. aeruginosa at physio

294 Oleate, linoleate, and arachidonate were all effective, but the saturated fatty

295 nces in Ca(2+) mobilization by TNF-alpha and arachidonate were reflected in spatial patterning in the

296 s from cholesteryl linoleate and cholesteryl arachidonate, were also present.

297 B sPLA2s are virtually inactive at releasing arachidonate when added exogenously to adherent cells.

298 is abstraction of the 13-proS hydrogen from arachidonate which, for PGG(2) formation, is followed by

299 The oxidation mixture of cholesteryl arachidonate, which has been characterized by a variety

300 In reactions of arachidonate with the model protein RNase, PM prevented